Sun Pharma's Q3FY24 consolidated gross sales hit Rs. 121,569 million, with a YoY growth of 9.5%. Notable increases in India and US formulation sales.
Source: BSE, Investor Presentation Q3 FY’24
Key financial indicators: EBITDA at Rs. 34,768 million (28.1% margin), adjusted net profit at Rs. 25,936 million (19.7% growth YoY). Robust R&D investments at Rs. 8,245 million.
Source: BSE, Investor Presentation Q3 FY’24
Gross sales for 9M FY24: Rs. 359,451 million (10.4% growth). Segment-wise sales and EBITDA at Rs. 99,880 million (27.4% margin). Net profit at Rs. 69,218 million.
Source: BSE, Investor Presentation Q3 FY’24
Board approved results and declared an interim dividend of Rs. 8.50 per share for FY24. Dilip Shanghvi, MD, pleased with broad-based growth, especially in Global Specialty.
Source: BSE, Investor Presentation Q3 FY’24
India formulation sales at Rs. 37,785 million (11.4% growth). Sun Pharma holds 8.5% market share, ranked No.1 by prescriptions in 12 doctor categories. Launched 28 new products in Q3FY24.
Source: BSE, Investor Presentation Q3 FY’24